Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Katharina Daugs MD

Postdoctoral Visiting Researcher

After completing my medical degree in 2023 and earning my MD with a focus on cardiovascular research, I began my clinical training in Pediatric Oncology at the University Hospital Düsseldorf, Germany. My primary research interest has centered on genetic predisposition to childhood cancers, contributing to our institution’s germline study.

In October 2025, I joined the Roy Lab at the University of Oxford as a clinical postdoctoral visiting researcher under the supervision of Professor Anindita Roy through a fellowship of the German Research Foundation. My current project focuses on developing innovative therapeutic strategies for KMT2A-rearranged (KMT2A-r) infant acute lymphoblastic leukemia, a highly aggressive subtype characterized by poor prognosis and central nervous system involvement. 

The study aims to evaluate the antileukemic efficacy of drugs in our KMT2A-BCP-ALL model, complemented by high-throughput drug screening to identify synergistic combination partners. The overarching goal is to elucidate underlying mechanisms of drug synergy and identify effective combination therapies capable of overcoming CNS barriers to improve clinical outcomes in KMT2A-r infant ALL.